Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

RZ Orlowski, A Nagler, Pieter Sonneveld, J Blade, R Hajek, A Spencer, JF San miguel, T Robak, A Dmoszynska, N Horvath, I Spicka, HJ Sutherland, AN Suvorov, SH Zhuang, T Parekh, L Xiu, Z Yuan, W Rackoff, JL Harousseau

Research output: Contribution to journalArticleAcademicpeer-review

595 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)3892-3901
Number of pages10
JournalJournal of Clinical Oncology
Publication statusPublished - 2007

Research programs

  • EMC MM-02-41-03

Cite this